longitudinal sections were made. The stain used for histology was AlcianBlue/Alizarin.

Results: The development of long bones in vitamin C deficient guinea pigs is considerably stagnant. Hyaline cartilage models are significantly shortened. Ossification in the diaphyses of carpal and metacarpal bones are absent, and the organization of the epiphysial plates is very irregular with the reduction of number of chondrocytes. Moreover, there are numerous haemorrhagic regions and subperichondrial bleeding with separation of perichondrium.

Conclusion: Deprivation of vitamin C during intrauterine period disables normal development of long bones. Disorder of hyaline cartilage models was seen, as well as the disorder of ossification.

http://dx.doi.org/10.1016/j.pbj.2017.07.085

PS060

Peculiarities of expression of apoptosis markers in the tissues of primary fallopian tubes carcinoma

Franklin Unawunwa, Natalia Hyriavenko, Anna Korobchanska, Mykola Lyndin, Vladyslav Sikora

Sumy State University
E-mail address: unawunwafranklin@yahoo.com (F. Unawunwa).

Aim: Immunohistochemical analysis of apoptosis markers in the tissue of PFTC.

Introduction: Primary fallopian tubes carcinoma is a rare case among oncological diseases of female genital organs, but the mortality rate is rather high. Nowadays, the prognostic factors of this neoplasia are not fully determined. The data on the p53 and bcl2 proteins expression and their use as prognostic factors in patients with malignant tumors of many locations are contradictory.

Methods: The study was conducted on 66 samples of fallopian tubes tumor tissue. To study the apoptosis peculiarities of tumor cells the mouse monoclonal antibodies for bcl-2 (clone 100/D5) and p53 (clone SP5) were used. Mathematical calculations were done using Microsoft Excel 2010 with AtteStat 12.0.5.

Results: The high expression of p53 was found in patients of all clinical stages. Mutations of p53 increased with spreading of the neoplastic process. Strong correlation of p53 presence in tumor samples and clinical stage of the disease was determined (r=0.77). In contrast to the abovementioned protein the study of bcl-2 showed the moderate negative correlation between this protein and the stage of the disease (r=−0.54). Analysis of the dependence of p53 expression with the presence or absence of lymph nodes metastasis showed a direct correlation between the indicators (r=0.25). Thus the level of p53 expression in patients with N1 was 80.6±2.7% compared with the N0 group (29.7±3.6%). The stage of neoplasia differentiation is in moderate direct correlation with p53 expression (r=0.58) and in inverse with bcl-2 (r=−0.64).

Conclusion: Expression of p53 depends on neoplasia spreading and stage of tumor differentiation. The expression of p53 is an independent prognostic marker for N-status and helps to classify the patients into “risk” groups.

Acknowledgements: Supervisor: A. M. Romaniuik, prof., doctor of medical sciences, Department of Pathological Anatomy, Medical Institute, Sumy State University.

http://dx.doi.org/10.1016/j.pbj.2017.07.086

PS064

Analysis of combined impact of doxorubicin and menadione on human leukemia Jurkat T cells

Alexandru Ionut Duta, Ioana Teodora Tofolean, Ramona Madalina Babes, Constanta Ganea, Irina Baran

“Carol Davila” University of Medicine and Pharmacy, Department of Biophysics, Bucharest, Romania
E-mail address: alexxxduta@yahoo.com (A.I. Duta).

Aim: The anti-proliferative effect and the mechanism of action of doxorubicin (DOX) in combination with menadione (MD) were studied in Jurkat T cells, a model for acute lymphoblastic leukaemia (ALL).

Introduction: Doxorubicin is a well-characterized and successful antineoplastic drug commonly used in various cancer treatments, including ALL. Menadione has proven a strong pro-apoptotic effect in Jurkat cells.1-3

Methods: Cell cycle, apoptosis/necrosis and the oxidative status were assessed by flow cytometry on propidium iodide, Annexin V-FITC/PI and CM-H2DCFDA/7-AAD labelled cells, respectively.

Results: Oxidative stress induced within 4 h by MD (IC50=11.5 μM) was reduced in the presence of 500 nM DOX (IC50=22.0 μM). After treatments of 18 h, DOX induced cell cycle arrest displaying a tri-modal distribution; successive G2/M, S and G0/G1 blockage was produced with an IC50 of 49 nM, 464 nM and 1866 nM, respectively, whereas in the presence of 7.5 μM MD, increasing levels of DOX mainly induced S-phase arrest. Within 18 hours of exposure, DOX induced apoptosis in a biphasic dose-dependent manner (Kd=335 nM and 3.29 μM, respectively). Addition of 7.5 μM MD enhanced apoptosis at <300 nM DOX, but reduced cell death at higher levels of DOX. However, 48 h after drug removal the apoptotic rate was considerably higher in cells exposed to DOX:MD, which also showed consistent fractions of early apoptosis (up to 44%). The efficacy of DOX was doubled by MD (Kd=46.5 nM in the presence, and Kd=99 nM and 143 nM in the absence of MD).

Conclusion: Data indicate that clinically relevant levels of MD and DOX in combined treatments can exert considerable cytotoxic impact on Jurkat cells, via cell cycle arrest and apoptosis induction. These findings could encourage new therapeutic strategies to improve the therapeutic index of doxorubicin in ALL treatments.

Acknowledgements: This work was supported by a fellowship of the Romanian Ministry of Education, UEFISCDI, for Young Researchers, project number 8/2016.

References

http://dx.doi.org/10.1016/j.pbj.2017.07.087

PS068

Effect of symptom interval and demographic characteristics on initial stage of malignant tumors in children

R. Grujić, O. Djurmez, M. Trkulja, J. Lazić, M. Bjelić

School of Medicine, University of Belgrade, Serbia
Aim: The aim of our retrospective study was to determine the
influence of demographic and clinical characteristics of patients,
initial stage of disease and tumor size on symptom period in chil-
dren with malignant tumors.

Introduction: One of the main goals in pediatric oncology is
timely diagnosis, cause it allows prompt and more effective treat-
ment and significantly decreases the number of complications. The
majority of children with malignant tumors have specific or non-
specific symptoms certain time period before the diagnosis which
can point towards malignant disease.

Methods: Our study included 296 children with malignant
tumors, diagnosed and

treated between 2005 and 2016 in University Children’s
Hospital in Belgrade. Collected data included sociodemographic
parameters, variety of symptoms and its duration, initial stage of
disease and size of the tumor.

Results: The most frequent tumors were as follows: neuroblas-
Non-Hodgkin lymphoma was diagnosed more frequently in boys,
while Ewing sarcoma and primitive neuroectodermal tumors were
seen mostly in girls. The majority was admitted at IV stage (30.1%)
in opposite to 13.5% of patients in I stage. The average symptom
interval was 87.7 days (median 46; SD = 164), from 5 to 2190 days.
We have proven that following factors have significant effect on the
extent of symptom interval: age (p < 0.001), type of tumor (p < 0.05),
its localization (p < 0.001), specific symptoms (p < 0.05), and ref-
erral from primary health care unit in comparison to secondary one
(p < 0.05).

Conclusion: The results of our study give a new insight in symp-
tom interval of children with malignant tumors in our country.
More detailed comprehension of patients’ characteristics, their dis-
ease, healthcare system and their effect on symptom interval could
significantly contribute to early diagnosis, as well as decreased
number of complications at admission and during treatment.

References
2. Little J. Epidemiology of Childhood Cancer. International agency for research on
tion in children and adolescents diagnosed with leukemia or lymphoma in Canada.
Int J Cancer. 2010;126:1936–43.
5. Wallach M, Balmer A, Munier F, Houghton S, Pampallona S. Shorter time to diag-
nosis and improved stage at presentation in Swiss patients with retinoblastoma
6. Veneroni L, Mariani L, Vullo S, Lo et al. Symptom interval in pediatric patients
with solid tumors: adolescents are at greater risk of late diagnosis. Pediatr Blood

http://dx.doi.org/10.1016/j.pbj.2017.07.088
PS069

Impact of prior malignancies on the outcome of colorectal cancer: Revisiting clinical trial
eligibility criteria

Anas M. Saad 1,∗, Muneer J. Al-Husseini 1,
Hadeer H. Mohamed 1, Mohamad A. Alkhayat 1,
Mohamad Bassam Sonbol 2,
Omar Abdel-Rahman 3

1 Faculty of Medicine, Ain Shams University, Cairo,
Egypt

2 Mayo Clinic Cancer Center, Phoenix, Arizona, USA
3 Faculty of Medicine, Ain Shams University, Clinical
Oncology, Cairo, Egypt

E-mail address: anassaad256@gmail.com
(A.M. Saad).

Aim: To study the impact of prior malignancies on the survival of
subsequent CRC.

Introduction: Colorectal cancer (CRC) is the third most common
cancer in the US.1–3 Some studies have correlated a prior history of
malignancy with an increased incidence of CRC. Patients with his-
tory of cancer are generally excluded in clinical trials. This practice,
not only affects clinical trials accrual, but also limits the potential
therapeutic options for this population. The rationale behind this
exclusion is that a history of malignancy could potentially interfere
with the study outcomes.4 However, little is known about its real
impact on survival of subsequent CRC.

Methods: We identified patients with CRC diagnosed between
1973 and 2008 using the National Cancer Institute’s SEER database.5–6 Outcomes of interest were overall survival and cause-
specific survival of subsequent CRC in general, and specifically
stage IV disease. Unadjusted Kaplan-Meier test and multivariable
covariate-adjusted Cox models were used to assess the eligibility
of enrollment of stage IV CRC patients in clinical trials.

Results: Overall, 550,325 patients with CRC were identified, of
whom 31,663 patients had a prior malignancy. Both, history of prior
non-leukemic malignancy and prior leukemia were associated with
a worse overall survival (HR = 1.165 95% CI = 1.148–1.183, P < 0.001)
and (HR = 1.825 95% CI = 1.691–1.970, P < 0.001), respectively. How-
ever, a history of any prior non-leukemic malignancy showed a
favorable colorectal-specific survival (HR = .930 95% CI = .909–.952,
P < 0.001). Analysis of stage IV CRC showed that a history of any
prior non-leukemic malignancy was not associated with a signifi-
cant difference in overall survival but having a history of leukemia
showed a worse overall survival (HR = 1.535, 95% CI = 1.303–1.809,
P < 0.001).

Conclusion: Clinical trials should take these results into consid-
eration when including/excluding stage IV CRC patients with prior
malignancies.

References
4. Laccetti AL, Pruitt SL, Xuán I, Halm EA, Gerber DE. Effect of prior cancer on
outcomes in advanced lung cancer: implications for clinical trial eligibility and
5. Surveillance Research Program, National Cancer Institute SEER*Stat software
(www.seer.cancer.gov/seerstat) version 8.3.3.
Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems
Branch, released April 2016, based on the November 2015 submission.

http://dx.doi.org/10.1016/j.pbj.2017.07.089
PS071

Intervention of diabetes mellitus and metabolic
risk factors in AMPK-PPC1α-SIRT3 pathway in
the human corpus cavernosum

A. Santos Pereira1,∗, A.R. Rodrigues1,
B. Rocha1,
N. Tomada2, A.M. Gouveia1,∗, D. Neves1

1 Mayo Clinic Cancer Center, Phoenix, Arizona, USA
2 Catholic University, Setubal, Portugal

E-mail address: robertogrujicic@gmail.com
(R. Grujicic).